Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography

2012/07/11 by David A Wolk, David A. Wolk, Zheng Zhang +7 · 1 citation
Medicine · Neuroscience · #Alzheimer's disease research and treatments #Dementia and Cognitive Impairment Research #Functional Brain Connectivity Studies

paper · doi:10.1136/jnnp-2012-302548

Abstract

BACKGROUND: Amyloid imaging provides in vivo detection of the fibrillar amyloid-β (Aβ) plaques of Alzheimer's disease (AD). The positron emission tomography (PET) ligand, Pittsburgh Compound-B (PiB-C11), is the most well studied amyloid imaging agent, but the short half-life of carbon-11 limits its clinical viability. Florbetapir-F18 recently demonstrated in vivo correlation with postmortem Aβ histopathology, but has not been directly compared with PiB-C11. METHODS: Fourteen cognitively normal adults and 12 AD patients underwent PiB-C11 and florbetapir-F18 PET scans within a 28-day period. RESULTS: Both ligands displayed highly significant group discrimination and correlation of regional uptake. CONCLUSION: These data support the hypothesis that florbetapir-F18 provides comparable information with PiB-C11.

Citations

• Neuropathological stageing of Alzheimer-related changes

Cited by

• DLMUSE: Robust Brain Segmentation in Seconds Using Deep Learning

Related

• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
• Aβ status assessment in a hypothetical scenario prior to treatment with disease‐modifying therapies: Evidence from 10‐year real‐world experience at university memory clinics
• Longitudinal Evaluation of ¹⁸ F-MK-6240 Along the Alzheimer Disease Continuum
• Complementary utility of plasma biomarkers and Aβ‐PET for diagnosis, risk‐stratification, and treatment monitoring in Alzheimer's disease
• Predicting cognitive decline with amyloid-PET, plasma p-tau217, Aβ42/40, and p-tau217/Aβ42 in a community-based cohort - relevance for clinical trial enrollment